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Objectives: For improvement of aiding effectiveness both for clinicians and spe-
cialists in the field of health care system one should know quality of patient’s life 
in different time period rating of the disease. MethOds: 70 cystic fibrosis (CF) 
children from Russia and CIS countries 5-16 years were interviewed using HUI ver-
sion 15Q, while children over 12 years responded on their own (self assessment), 
information about children younger 12 years was obtained from parents (proxy 
assessment) .Version was translated into russian language and adapted. HUI cur-
rently consists of two systems: HUI Mark 2 and HUI Mark 3. Each HUI2 and HUI3 
classification system consists of attributes (domains) of health and 3 to 6 levels of 
functional ability/disability within each attribute and is very responsive to changes 
and to highlight avenues of additional study. Single-attribute utility scores and 
multi-attribute utility scores evaluated corresponding to each system, ranges from 
0 to 1. Results: Mean Mark 2 has a tendency to increase from 0,85 in children 
5 years to 0,95 in children 15 years with reduction in 6 years (0,80), 12 years (0,85) 
and 16 years (0,85). Same tendency was observed in Mark 3: 6 years- 0,75; 12 years- 
0,75; 16 years- 0,77 cOnclusiOns: Decrease of quality of life in above mentioned 
ages is a result of unadequate treatment in children living in some regions of CIS 
and severe complications of CF in older children also.
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Objectives: Diurnal variation in symptoms and functioning is a feature of 
Parkinson’s disease, referred to as ‘on’ and ‘off time’. Typically patient reported 
outcomes (PROs) don’t capture this variability or its value, instead requesting par-
ticipants report over the last day or week. This study evaluated the impact and value 
of ‘on’ and ‘off time’ for people with Parkinson’s (PwP) by assessing their HRQL and 
strength of preference. MethOds: PwP from UK, Spain, France and Italy (n= 305), 
experiencing ≥ 2 hours ‘off time’ daily, completed EQ-5D-5L assessments for ‘on’ 
and ‘off time’ that day, followed by a discrete choice experiment (DCE) evaluating 5 
treatment attributes: duration of ‘on time’; quality of ‘off time’; predictability of ‘off 
time’; feelings of anxiety/depression, and dosing frequency. The DCE was informed 
by qualitative work with patients (n= 20), carers (n= 6) and health professionals (n= 6) 
in UK and Spain and employed an orthogonal, factorial, fold-over design. Analysis 
used the mixed-logit model and effects coding of categorical levels (predictability of 
off-time attribute). Results: Mean EQ-5D utility values were significantly lower for 
‘off time’ (0.37, 95%CI: 0.33-0.40) than ‘on time’ (0.60, 95%CI: 0.57-0.62). All attributes 
were significant drivers of treatment choice. PwP valued increased duration of ‘on 
time’ (per hour per day: OR= 1.40, 95%CI 1.31-1.45) and predictability of ‘off time’ 
most highly (predictability to within 30 minutes of symptoms returning: OR= 1.42, 
95%CI 1.15-1.57). High disutility was reported for substantial unpredictablility of ‘off 
time’ (OR= 0.67, 95%CI 0.49-0.91). cOnclusiOns: Important differences in quality 
of life between ‘on’ and ‘off time’ were found which could be missed by standard 
PRO assessment, including the relative value that PwP placed on increased dura-
tion of ‘on time’ and predictability of ‘off time’. Assessments and interpretation of 
outcomes in Parkinson’s should consider diurnal variation. Capturing this variation 
and its value may require modifications to PRO design. [Study HO-11-802]
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Objectives: Albeit effectiveness of subcutaneous treatments for Multiple 
Sclerosis (MS) has been demonstrated, adverse reactions and pain may entail prob-
lems regarding treatment satisfaction and continuity. This study aims to adapt 
and validate the Spanish version of the “Multiple Sclerosis Treatment Concerns 
Questionnaire-MSTCQ”, which evaluates satisfaction with the injection device (ID) 
in 4 dimensions: Injection system (A), Side-effects (B) (flu-like symptoms, reactions, 
and satisfaction), Treatment experience (C) and Benefits (D). MethOds: Two Stages: 
1) Cultural adaptation: Forward-backward translation and expert (n= 6) and patient 
(n= 30) panels; 2) Validation: Observational, cross-sectional, multicenter study. A 
total of 143 adult patients suffering from MS and using an ID were evaluated. Tools 
employed: MSTCQ, Patient-Reported Indices for Multiple Sclerosis (PRIMUS), Treatment 
Satisfaction Questionnaire for Medication (TSQM), Morisky Green and Patient Injection 
Site Reaction (ISR) and Injection Site Pain (ISP). Psychometric properties: Feasibility 
(% valid cases and ground/ceiling effects); Reliability (Cronbach α ) and test-retest 
(41 patients, Intraclass Correlation Coefficient, ICC); as well as construct (Factorial 
analysis of dimensions A and B, FA) and convergent (Spearman MSTCQ vs. TSQM) 
validity. Results: Mean age(SD) in cases was 41,94(10,47) years, 63% female, 88,11% 
suffering from Relapsing-Remitting MS. MSTCQ feasibility was adequate (missing 
0%-2,80%). High internal consistency, total score (A+B) α = 0, 89, by dimensions α (A, 
B and C): 0,76, 0,89 and 0,92, respectively. Furthermore, a concordance was found 
between total (ICC= 0, 98) and by dimensions ICC (A, B and C) scores: 0,82, 0,97 and 
0,89, respectively. The FA confirms dimensions A and B from the original question-
naire. Lastly, the association between total and by dimensions scores, from MSTCQ 
and TSQM was, overall, moderately strong (Rho between-0, 74, y 0, 42) and significant 
isfaction and preferences for MS treatments. Bibliographic references were hand 
searched. English or Spanish studies published between January 2007 and January 
2013 were selected. Results: A total of 398 citations were identified; 12 studies 
accomplished the inclusion criteria. Six referred to PROs and treatment costs; 4 
analyzed satisfaction with disease-modifying therapies (DMTs) and 2 assessed pref-
erences for treatment attributes. An increased adherence and persistence on DMTs 
was associated to higher pharmacy costs and to better clinical outcomes [lower 
relapse risk (OR= 0.71 CI 95%, 0.59-0.85); decreased MS hospitalizations (OR= 0.63, 
CI 95%, 0.47 – 0.83)] leading to a cost reduction of up to 22% patient/year. DMT 
adherent patients had a significantly lower rate of severe relapses (12.5% vs. 19.5%; 
p= 0.0200), lower MS-related or all-causes medical (7.6% vs. 12.5%; p= 0.0447 and 
11.2% vs. 20.0%; p= 0.0027) and emergency visits (8.9% vs. 15.0%; p= 0.0215 and 34.6% 
vs. 43.5%; p= 0.0305) than non-adherent. MS-related and all-cause inpatient costs 
(354.77±2.485.03 vs. 853.13±3,635.48; p= 0.0270 and 648.71±3,753.74 vs. 62.51±265.23; 
p= 0.0018) as well as emergency visit costs (46.46±255.94 vs. 1,740.88±6,127.27; 
p= 0.0076 and 147.82±430.79 vs. 242.42±592.96; p= 0.0044) were significantly lower 
in adherent patients. Self-injection [Visual Analogue Scale (VAS) mean 6.9; range 
0-10] render higher treatment satisfaction. Slower disability progression (efficacy) 
was the most preferred attribute (p< 0,001). Newly developed electronic devices 
that allow adjusting injection settings as well as adherence objective monitoring 
appeal more to patients (VAS mean 7.7; range 0-10) than more traditional methods 
of administration. cOnclusiOns: MS studies assessing adherence and costs are 
scarce. Treatments and devices better tailored to patients’ needs improve adherence, 
enhance clinical outcomes and procure a reduction on MS costs.
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Objectives: To present health state values (QALY weights) for multiple scle-
rosis (MS) health states using data from a prospective, longitudinal, cohort 
study. MethOds: Data from a large UK cohort study for MS, the South West Impact 
of MS (SWIMS) Study, were used for analysis. SWIMS data comprise six-monthly 
self-report assessments, including EQ-5D and SF-36 health status measures, and 
data on relapse frequency/severity. Self-report data is supplemented with data 
from clinician assessment of disability using the EDSS. Health state valuation data 
are sourced from published UK tariffs (EQ-5D and SF-6D) to present values for MS 
against EDSS, relapse characteristics, and against other disease related characteris-
tics. Results: Analyses of SWIMS data included 1,441 respondents, over an average 
of 8 time-points. Findings on health state values show a health profile that wors-
ens by disease progression, against EDSS stages, using both the EQ-5D and SF-6D 
methods. Health state values estimated from EQ-5D data range from 0.76 at EDSS 
stage 1.0 to 0.03 at EDSS stage 8, with lower values seen for progressive MS. Values 
estimated from SF-36 data reflect the narrower range of values possible on the SF6D 
tariffs, with values from 0.7 to 0.53 across EDSS stages 1.0 to 8. Findings demonstrate 
impact on health state values due to relapse events, with this impact reported at 
0.08 using the EQ-5D and at 0.05 using the SF-6D. The impact of relapse frequency, 
severity and endurance on health has also been assessed. cOnclusiOns: This 
study presents health state valuation data derived from a high quality longitudinal 
cohort study, including values (QALY weights) for features/characteristics of relapse 
events in people with MS. This data can support improvements in the conduct of 
cost-effectiveness analyses of treatments for MS, and can be helpful in a general 
health policy context.
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Objectives: To assess the association between burden experienced by caregivers 
of patients with fragile X syndrome (FXS) in the United States and a health state 
utilities index derived from the Aberrant Behavior Checklist-Community (ABC-
C). MethOds: A total of 340 US caregivers of children with FXS completed a ques-
tionnaire that captured information on FXS-related burden (i.e., specialist visits, 
medical tests, medications, financial burden, employment status, paid and unpaid 
caregiving, caregiver injuries, and mental health). Using the ABC-Utility Index 
(ABC-UI), an estimate of health-related quality-of-life derived from the ABC-C, five 
utility index categories were created: very low (0.00–0.33); low (0.34–0.66); moderate 
(0.67–0.77); high (0.78–0.89); and very high (0.90–1.00). After controlling for sex, age, 
overall ability level, and income, multivariable regression models documented the 
association between utility score and the nine burden-related outcomes. Results: 
Respondents (283 with FXS male child; 57 with FXS female child) were mostly female 
(91%), Caucasian (92%), and married (84%), with mean age of 50 years. Approximately 
2% of individuals with FXS were in the very low utility category, 30.6% low, 27.1% 
moderate, 37.6% high, and 2.6% very high. The mean utility score was 0.71. Females 
with FXS and adults ≥ 18 years had higher health utilities. Results from regression 
models indicate that increasing utility values reduced the likelihood of ≥ 5 (vs. < 5) 
specialist visits (b= -4.583; p< 0.001) and ≥ 2 (vs. 0 or 1) prescription medications 
used (b= -4.517; p< .001). Similarly, increasing utility score was associated with a 
decreased likelihood of ≥ 8 (vs. < 8) hours of unpaid caregiving (b= -2.723; p= 0.003), 
≥ 1 (vs. 0 or 1) caregiver injuries (b= -7.540; p< 0.001), and ≥ 1 (vs. 0) mental health 
provider visits (b= -2.613; p= 0.002). cOnclusiOns: The ABC-UI appears to function 
well as a health-related quality-of-life indicator in individuals with FXS. Among 
caregivers of patients with FXS in the US, significant differences in burden exist 
across health state utilities.
